Key Points
- Major insider purchase: Rick Yang bought 207,100 shares at an average of $11.11 per share (≈$2.3M), increasing his stake ~18.99% to 1,297,893 shares (≈$14.42M) per the SEC filing.
- Weak earnings but modest revenue beat: Korro reported a Q4 EPS loss of ($5.32) versus a consensus of (−$1.93) and very negative margins, although revenue of $1.29M modestly beat estimates; shares recently traded near $12.99 with a market cap of about $122.4M.
- Balance sheet and pipeline developments: Management completed an oversubscribed $85M private placementOutperform with a $23 target.
Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) major shareholder Anthony Jr. Florence purchased 207,100 shares of Korro Bio stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average price of $11.11 per share, with a total value of $2,300,881.00. Following the acquisition, the insider owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This represents a 18.99% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Korro Bio Stock Up 12.6%
Shares of NASDAQ KRRO traded up $1.45 during midday trading on Friday, reaching $12.95. 552,892 shares of the company's stock traded hands, compared to its average volume of 237,193. The stock's 50 day simple moving average is $10.90 and its 200-day simple moving average is $20.23. Korro Bio, Inc. has a one year low of $5.20 and a one year high of $55.89. The company has a market cap of $121.97 million, a price-to-earnings ratio of -1.38 and a beta of 2.98.
Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($5.32) EPS for the quarter, missing analysts' consensus estimates of ($1.93) by ($3.39). The business had revenue of $1.29 million during the quarter, compared to the consensus estimate of $0.43 million. Korro Bio had a negative return on equity of 68.87% and a negative net margin of 1,199.53%. Equities analysts predict that Korro Bio, Inc. will post -9.52 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages recently weighed in on KRRO. Weiss Ratings restated a "sell (d-)" rating on shares of Korro Bio in a research note on Friday, January 9th. Wall Street Zen downgraded shares of Korro Bio from a "hold" rating to a "sell" rating in a report on Saturday, December 13th. Clear Str raised shares of Korro Bio from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 18th. Chardan Capital upgraded shares of Korro Bio from a "neutral" rating to a "buy" rating and set a $15.00 price target on the stock in a report on Thursday, January 29th. Finally, Royal Bank Of Canada downgraded shares of Korro Bio from an "outperform" rating to a "sector perform" rating in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $44.50.
View Our Latest Stock Report on Korro Bio
Institutional Investors Weigh In On Korro Bio
A number of large investors have recently modified their holdings of the business. Russell Investments Group Ltd. acquired a new position in shares of Korro Bio during the third quarter valued at about $39,000. CWM LLC raised its position in shares of Korro Bio by 391.4% in the 3rd quarter. CWM LLC now owns 2,693 shares of the company's stock valued at $129,000 after purchasing an additional 2,145 shares during the last quarter. PNC Financial Services Group Inc. acquired a new stake in Korro Bio in the 3rd quarter worth approximately $140,000. Wealth Forward LLC acquired a new stake in Korro Bio in the 3rd quarter worth approximately $240,000. Finally, Algert Global LLC purchased a new stake in Korro Bio during the 3rd quarter worth approximately $340,000. Hedge funds and other institutional investors own 13.18% of the company's stock.
More Korro Bio News
Here are the key news stories impacting Korro Bio this week:
- Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target (~74% upside vs. the recent share level), which can attract momentum buyers and institutional interest. Raymond James Upgrade
- Positive Sentiment: Multiple large shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed purchases of ~207,100 shares each at about $11.11 (~$2.3M per filing), increasing their stakes — a strong insider/major‑holder vote of confidence that can support the stock. Insider / Major Holder Buys
- Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for potential treatment of hyperammonemia, is advancing a GalNAc candidate for alpha‑1 antitrypsin deficiency (on track for a development candidate nomination in Q2 2026), and completed an oversubscribed $85M private placement — management says cash runway now extends into H2 2028, reducing near‑term financing risk. Corporate Update & Cash Raise
- Neutral Sentiment: Revenue modestly beat expectations ($1.29M vs. ~$0.42M est.), showing some commercial or other revenue pickup, but the dollar amounts are small relative to R&D burn — limited immediate impact on profitability. Earnings Press Release
- Negative Sentiment: Large quarterly loss: KRRO reported a Q4 EPS loss of ($5.32) vs. consensus (~($1.93)), driving very negative margins and return‑on‑equity metrics — a reminder of high execution risk and binary clinical development outcomes that can trigger volatility. Q4 Results & EPS Miss
About Korro Bio
(
Get Free Report)
Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company's proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.
The company's pipeline features both engineered enzyme therapeutics and live biotherapeutics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
